Open enrollment season is almost upon us. That will bring a test of whether the website for the federal exchange, HealthCare.gov can perform better in its second year than in its disastrous debut.
Open enrollment season is almost upon us. That will bring a test of whether the website for the federal exchange, HealthCare.gov, can perform better in its second year than in its disastrous debut.
On Friday, a notice on the site said it would undergo maintenance over the next several weekends, to prepare for the start of 2015 open enrollment under the Affordable Care Act. Another notice announces four key dates:
If there’s a word to sum up how insurers view upcoming enrollment season, it’s “anticipation.” A recent survey by the Kaiser Family Foundation found that rates in benchmark Marketplace plans declined slightly overall, but was wide variability among states, insurers and plans.
That has some experts wondering whether there will be lots of shopping going on, and if insurers will get adequate notice if a Marketplace customer has left for a new plan. That’s because there are a number of reports that much work remains on the “back end” of HealthCare.gov, which would provide insurers this kind of information.
Meanwhile, Kaiser’s 2014 employer benefits survey forecast a 3 percent increase nationally. Forbes, meanwhile, is reporting that a McKinsey study of the silver plans found an average increase of 8 percent, an important figure because subsidies are keyed to these plans.
Around the Web
Premiums Set to Decline Slightly for Benchmark ACA Marketplace Insurance Plans in 2015
2014 Employer Health Benefits Survey
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More